<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067898</url>
  </required_header>
  <id_info>
    <org_study_id>HUS-S-D-II</org_study_id>
    <secondary_id>2009-018139-98</secondary_id>
    <secondary_id>KLnro 1/2010</secondary_id>
    <nct_id>NCT01067898</nct_id>
  </id_info>
  <brief_title>A Study on Oral Vitamin D Megadoses</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Study on Oral Vitamin D Megadoses - 100 000 or 200 000 IU Vitamin D3 Every Three Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if infrequent administration of oral vitamin D
      megadoses is effective treatment to maintain serum 25-hydroxyvitamin D(3) above target levels
      of 50-75 nmol/L. The investigators hypothesize that 100 000 IU or at least 200 000 IU vitamin
      D3 in every three months would be effective and safe treatment to achieve the target levels.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum 25(OH)D3 concentration in relation to the target levels of 50-75 nmol/L</measure>
    <time_frame>12 months (including 9 time points)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decline of creatine clearance (Pt-GFRe-CG) &gt;20% from baseline</measure>
    <time_frame>12 months (including 9 timepoints)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalciuria (dU-Ca &gt;10 mmol/24h)</measure>
    <time_frame>12 months (including 9 timepoints)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hypercalcemia (S-Ca-ion &gt;1,3 mmol/l)</measure>
    <time_frame>12 months (including 9 timepoints)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PTH</measure>
    <time_frame>12 months (including 9 timepoints)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum PINP</measure>
    <time_frame>12 months (including 5 timepoints)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum CTX</measure>
    <time_frame>12 months (including 5 timepoints)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>200 000 IU vitamin D3 every three months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>100 000 IU vitamin D3 every three months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo every three months</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>vitamin D3 (cholecalciferol)</intervention_name>
    <description>vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.</description>
    <arm_group_label>200 000 IU vitamin D3 every three months</arm_group_label>
    <arm_group_label>100 000 IU vitamin D3 every three months</arm_group_label>
    <other_name>Vigantol vitamin D3 (cholecalciferol) oil 20 000 IU/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>olive oil</intervention_name>
    <description>10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year</description>
    <arm_group_label>100 000 IU vitamin D3 every three months</arm_group_label>
    <arm_group_label>placebo every three months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium carbonate</intervention_name>
    <description>1000 mg calcium per os every day for one year</description>
    <arm_group_label>200 000 IU vitamin D3 every three months</arm_group_label>
    <arm_group_label>100 000 IU vitamin D3 every three months</arm_group_label>
    <arm_group_label>placebo every three months</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  70-80 yrs old

        Exclusion Criteria:

          -  disease or medication affecting calcium homeostasis

          -  renal failure (Pt-GFRe-CG &lt; 35 ml/min)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Pekkarinen T, Välimäki VV, Aarum S, Turpeinen U, Hämäläinen E, Löyttyniemi E, Välimäki MJ. The same annual dose of 292000 IU of vitamin D (cholecalciferol) on either daily or four monthly basis for elderly women: 1-year comparative study of the effects on serum 25(OH)D concentrations and renal function. Clin Endocrinol (Oxf). 2010 Apr;72(4):455-61. doi: 10.1111/j.1365-2265.2009.03637.x. Epub 2009 May 25.</citation>
    <PMID>19486025</PMID>
  </reference>
  <reference>
    <citation>Välimäki VV, Löyttyniemi E, Välimäki MJ. Vitamin D fortification of milk products does not resolve hypovitaminosis D in young Finnish men. Eur J Clin Nutr. 2007 Apr;61(4):493-7. Epub 2006 Nov 29.</citation>
    <PMID>17136043</PMID>
  </reference>
  <reference>
    <citation>Välimäki VV, Alfthan H, Lehmuskallio E, Löyttyniemi E, Sahi T, Stenman UH, Suominen H, Välimäki MJ. Vitamin D status as a determinant of peak bone mass in young Finnish men. J Clin Endocrinol Metab. 2004 Jan;89(1):76-80.</citation>
    <PMID>14715830</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2010</study_first_submitted>
  <study_first_submitted_qc>February 11, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2010</study_first_posted>
  <last_update_submitted>March 26, 2012</last_update_submitted>
  <last_update_submitted_qc>March 26, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Ville-Valtteri Välimäki</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>vitamin D supplementation</keyword>
  <keyword>cholecalciferol</keyword>
  <keyword>PTH</keyword>
  <keyword>bone turnover markers</keyword>
  <keyword>elderly women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

